UCB announces European Commission approval of ZILBRYSQ®▼ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis

UCB announces European Commission approval of ZILBRYSQ®▼ (zilucoplan) for the treatment of adults with generalized Myasthenia GravisEuropean approval of ZILBRYSQ® (zilucoplan) granted as an add-on to standard therapy for the treatment of generalized Myasthenia Gravis (gMG) in adult patients who are anti-acet...

Related Keywords

Australia ,Canada ,Norway ,Belgium ,Liechtenstein ,Brussels ,Bruxelles Capitale ,China ,Iceland ,Japan ,Japanese ,Australian ,Jean Christophe Tellier ,Howard Jf Jr ,Laurent Schots ,Jim Baxter ,Antje Witte ,Health Canada ,Global Rare Disease Communications ,Australian Therapeutic Goods Administration ,Twitter ,Drug Administration ,European Commission ,European Medicines Agency ,Myasthenia Gravis Foundation Of America ,Japanese Ministry Of Health ,Corporate Communications ,National Institute Of Neurological Disorders ,Myasthenia Gravis ,Medicinal Products ,Human Use ,Euronext Brussels ,Lancet Neurology ,Product Characteristics ,Japanese Ministry ,European Economic Area ,Generalized Myasthenia Gravis ,Myasthenia Gravis Activities ,Daily Living ,Quantitative Myasthenia Gravis ,Myasthenia Gravis Composite ,Myasthenia Gravis Quality ,Priority Review ,Biologic License Application ,Drug Evaluation ,China National Medical Products Administration ,Important Safety ,Neurological Disorders ,Gravis Fact ,Accessed December ,Accessed October ,Gravis Foundation ,